newsfilter
← Latest News
GlobeNewswire·

Outlook Therapeutics to Present at Wet AMD and DME Drug Development Summit

ISELIN, N.J., April 05, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today anno